Arcadia Biosciences (RKDA) 10-K 28 Mar 24 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 21, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		1,362,840
Entity Public Float			$ 4,169,072
Stock price			$ 3.88
Entity Listing, Par Value Per Share	$ 0.001
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	5950 Sherry Lane
Entity Address, Address Line Two	Suite 215
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75225
City Area Code	214
Local Phone Number	974-8921
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	Information required by Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant's Definitive Proxy Statement for its 2022 Annual Meeting of Stockholders, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP
Auditor Location	Tempe, AZ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,518	$ 20,644
Short-term investments	5,124	0
Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 and $3 as of December 31, 2023 and 2022, respectively	514	1,221
Inventories, net — current	1,958	2,321
Assets held for sale	51	87
Prepaid expenses and other current assets	807	795
Current assets of discontinued operations	0	330
Total current assets	14,972	25,398
Property and equipment, net	384	680
Right of use assets	792	1,848
Inventories, net — noncurrent	3,354	767
Intangible assets, net	39	40
Other noncurrent assets	164	165
Noncurrent assets of discontinued operations	0	24
Total assets	19,705	28,922
Current liabilities:
Accounts payable and accrued expenses	2,410	2,855
Operating lease liability - current	852	1,010
Current liabilities of discontinued operations	0	26
Total current liabilities	3,590	4,209
Operating lease liability - noncurrent	155	1,007
Common stock warrant and option liabilities	1,257	806
Other noncurrent liabilities	2,000	2,000
Total liabilities	7,002	8,022
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $0.001 par value-150,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 1,285,337 and 616,079 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.	65	65
Additional paid-in capital	284,515	278,827
Accumulated other comprehensive income	101	0
Accumulated deficit	(271,840)	(257,859)
Total Arcadia Biosciences stockholders’ equity	12,841	21,033
Non-controlling interest	(138)	(133)
Total stockholders' equity	12,703	20,900
Total liabilities and stockholders’ equity	19,705	28,922
Related Party [Member]
Current liabilities:
Other current liabilities	58	48
Nonrelated Party [Member]
Current liabilities:
Other current liabilities	$ 270	$ 270

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 0	$ 3,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	1,285,337	616,079
Common stock, outstanding	1,285,337	616,079

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 5,330,000	$ 7,418,000
Operating expenses (income):
Cost of revenues	3,300,000	6,101,000
Research and development	1,387,000	1,509,000
Gain on sale of Verdeca	0	(1,138,000)
Impairment of intangible assets	0	141,000
Change in fair value of contingent consideration	0	(70,000)
Gain on sale of property and equipment	(40,000)	(314,000)
Impairment of property and equipment, net	0	160,000
Impairment of ROU asset	113,000	0
Selling, general and administrative	14,508,000	15,036,000
Total operating expenses	19,268,000	21,425,000
Loss from operations	(13,938,000)	(14,007,000)
Interest income	695,000	289,000
Other income, net	48,000	9,000
Valuation loss on March 2023 PIPE	(6,076,000)	0
Change in fair value of common stock warrant and option liabilities	6,544,000	3,209,000
Issuance and offering costs allocated to liability classified options	(430,000)	(314,000)
Net loss from continuing operations before income taxes	(13,157,000)	(10,814,000)
Income tax expense	(8,000)	(14,000)
Net loss from continuing operations	(13,165,000)	(10,828,000)
Net loss from discontinued operations	(821,000)	(4,784,000)
Net loss	(13,986,000)	(15,612,000)
Net loss attributable to non-controlling interest	(5,000)	(236,000)
Net loss attributable to common stockholders	$ (13,981,000)	$ (15,376,000)
Net loss per share attributable to common stockholders:
Basic net loss per share attributable to common stockholders from continuing operations	$ (10.64)	$ (17.67)
Diluted net loss per share attributable to common stockholders from continuing operations	(10.64)	(17.67)
Basic net loss per share attributable to common stockholders from discontinued operations	(0.66)	(7.98)
Diluted net loss per share attributable to common stockholders from discontinued operations	$ (0.66)	$ (7.98)
Weighted-average number of shares used in per share calculations:
Weighted average shares - Basic	1,236,934	599,389
Weighted average shares - Diluted	1,236,934	599,389
Unrealized gains on available-for-sale securities	$ 101,000	$ 0
Other comprehensive income	101,000	0
Comprehensive loss attributable to common stockholders	(13,880,000)	(15,376,000)
Product
Revenues:
Total revenues	5,313,000	6,422,000
License
Revenues:
Total revenues	17,000	879,000
Royalty
Revenues:
Total revenues	$ 0	$ 117,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	August 2022 Offering [Member]	March 2023 PIPE [Member]	Common Stock [Member]	Common Stock [Member] August 2022 Offering [Member]	Common Stock [Member] March 2023 Offering [Member]	Common Stock [Member] March 2023 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] August 2022 Offering [Member]	Additional Paid-In Capital [Member] March 2023 PIPE [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-Controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2021	$ 31,196			$ 63				$ 257,515			$ (226,485)		$ 103
Stockholders Equity, Beginning Balance (Accounting Standards Update 2020-06 Retrospective [Member]) at Dec. 31, 2021	$ 3,392							19,390			(15,998)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2021				554,609
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Issuance of shares related to August 2022 pre-funded warrants exercise	0
Issuance of shares		$ 1,176			$ 2				$ 1,174
Issuance of shares, Shares					61,250
Offering costs		$ (365)							$ (365)
Issuance of shares related to employee stock purchase plan	$ 7							7
Issuance of shares related to employee stock purchase plan, Shares				220
Stock-based compensation	1,106							1,106
Net loss	(15,612)										(15,376)		(236)
Stockholders Equity, Ending Balance at Dec. 31, 2022	$ 20,900			$ 65				278,827			(257,859)		(133)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2022				616,079
Issuance of shares related to August 2022 pre-funded warrants exercise	(482,647)
Issuance of shares			$ 4,740				$ 0			$ 4,740
Issuance of shares, Shares					56,813	425,834	165,500
Modification of warrants related to March 2023 PIPE			$ 219							$ 219
Unrealized gains on available-for-sale securities												$ 101
Issuance of shares related to exercise of Service and Performance Warrants	$ 0							0
Issuance of shares related to reverse stock split, Shares	19,118			19,118
Issuance of shares related to employee stock purchase plan	$ 12							12
Issuance of shares related to employee stock purchase plan, Shares				1,993
Stock-based compensation	717							717
Net loss	(13,986)										(13,981)		(5)
Stockholders Equity, Ending Balance at Dec. 31, 2023	$ 12,703			$ 65				$ 284,515			$ (271,840)	$ 101	$ (138)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2023				1,285,337

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,986,000)	$ (15,612,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant and option liabilities	(6,544,000)	(3,209,000)
Change in fair value of contingent consideration	0	(70,000)
Issuance and offering costs allocated to liability classified options	430,000	314,000
Valuation loss on March 2023 PIPE	6,076,000	0
Depreciation	287,000	439,000
Amortization of intangible assets	0	40,000
Lease amortization	697,000	884,000
Impairment of intangible assets	0	404,000
Gain on disposal of equipment	(40,000)	(314,000)
Stock-based compensation	717,000	1,106,000
Bad debt expense	20,000	60,000
Gain on sale of Verdeca	0	(1,138,000)
Write-down of inventories	444,000	2,471,000
Impairment of property and equipment	0	530,000
Impairment of ROU asset	113,000	0
Changes in operating assets and liabilities:
Accounts receivable and other receivables	184,000	592,000
Inventories	(2,419,000)	1,118,000
Prepaid expenses and other current assets	1,000	91,000
Other noncurrent assets	2,000	16,000
Accounts payable and accrued expenses	(522,000)	(757,000)
Amounts due to related parties	10,000	(16,000)
Other current liabilities	0	6,000
Operating lease payments	(764,000)	(932,000)
Net cash used in operating activities	(15,294,000)	(13,977,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	115,000	920,000
Proceeds from sale of Verdeca - earn-out received	569,000	569,000
Proceeds from sale of investments	2,502,000	0
Purchases of property and equipment	(5,000)	(72,000)
Purchases of investments	(7,525,000)	0
Net cash (used in) provided by investing activities	(4,344,000)	1,417,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from ESPP purchases	12,000	7,000
Net cash provided by financing activities	5,512,000	4,519,000
Net decrease in cash and cash equivalents	(14,126,000)	(8,041,000)
Cash and cash equivalents - beginning of period	20,644,000	28,685,000
Cash and cash equivalents - end of period	6,518,000	20,644,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	0	1,000
NONCASH TRANSACTIONS:
Right of use assets obtained in exchange for new operating lease liabilities	0	114,000
Proceeds from sale of property and equipment in accounts receivable and other receivables	8,000	19,000
Proceeds from sale of Verdeca in accounts receivable and other receivables	0	569,000
Accounting Standards Update 2020-06 [Member]
NONCASH TRANSACTIONS:
Common stock warrant liabilities reclassified to equity upon adoption of ASU 2020-06	0	3,392,000
August 2022 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE	0	5,000,000
Payments of offering costs relating to March 2023 PIPE	0	(488,000)
August 2022 RDO Securities Purchase Agreement [Member]
NONCASH TRANSACTIONS:
Common stock options issued to placement agent and included in offering costs	0	191,000
March 2023 PIPE [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE	5,997,000	0
Payments of offering costs relating to March 2023 PIPE	(497,000)	0
NONCASH TRANSACTIONS:
Common stock options issued to placement agent and included in offering costs	212,000	0
Warrant and option modifications included in Valuation loss on March 2023 PIPE	$ 404,000	$ 0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (13,981)	$ (15,376)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California, and additional facilities in American Falls, Idaho. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based food and beverage products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The acquisition of the assets of Live Zola, LLC (“Zola”) added coconut water to the Company's portfolio of products. In May 2021, the Company's wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”), acquired the businesses of Eko, Lief, and Zola. The acquisition included Saavy Naturals™, a line of natural body care products, Soul Spring™, a CBD-infused botanical therapy brand in the natural category, and ProVault™, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively "body care brands"). Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. On July 8, 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased as of September 30, 2023. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 6) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $ 10.0 million on sales of Haab 4 soybeans (“HB4”). An additional $ 2.0 million in cash is to be paid to Arcadia upon Verdeca of achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for “food and feed”. During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $ 862,000 and a gain on sale of Verdeca of $ 1.1 million on the consolidated statements of operations and comprehensive loss. The Company received the full payment of $ 2.0 million as of December 31, 2023. Reverse Stock Split In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock. On F ebruary 15, 2023, the Company’s stockholders approved the certificate of amendment to the Company’s certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2023, the Company had an accumulated deficit of $ 271.8 million, cash and cash equivalents of $ 6.5 million and short-term investments of $ 5.1 million. For the years ended December 31, 2023 and 2022, the Company had net losses of $ 14.0 million and $ 15.6 million, respectively, and net cash used in operations of $ 15.3 million and $ 14.0 million, respectively. The Company believes that its existing cash and cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition. Discontinued Operations In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased as of September 30, 2023. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets and the results of the discontinued operations as a separate component of loss on the consolidated statements of operations and comprehensive loss for all periods presented. Major classes of line items constituting the balance sheet of discontinued operations: (In thousands) December 31, 2023 December 31, 2022 Assets Accounts receivable and other receivables $ — $ 66 Inventories, net — current — 250 Prepaid expenses and other current assets — 14 Property and equipment, net — 24 Total assets $ — $ 354 Liabilities Accounts payable and accrued expenses $ — $ 26 Total liabilities $ — $ 26 Major classes of line items constituting net loss from discontinued operations: Year Ended December 31, 2023 2022 (In thousands) Product revenue $ 357 $ 2,537 Cost of revenues ( 314 ) ( 3,700 ) Impairment of intangible assets — ( 263 ) Impairment of property and equipment — ( 371 ) Selling, general and administrative ( 864 ) ( 3,011 ) Other income, net — 24 Net loss from discontinued operations $ ( 821 ) $ ( 4,784 ) The following table presents significant non-cash items of discontinued operations: Year Ended December 31, (In thousands) 2023 2022 Depreciation $ 24 $ 88 Impairment of intangible assets $ — $ 263 Write-down of inventories $ — $ 1,369 Impairment of property and equipment $ — $ 371 Accounts receivable and other receivables $ 66 $ 588 Inventories $ 250 $ ( 251 ) Prepaid expenses and other current assets $ 14 $ 132 Accounts payable and accrued expenses $ ( 26 ) $ ( 415 ) There were no other significant operating or investing non-cash items for the years ended December 31, 2023 and 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 5,000 and $ 236,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2023 and 2022, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the consolidated balance sheets as of December 31, 2023 and 2022. Reclassifications Certain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former body care brands reported as discontinued operations, see “Discontinued Operations” section above. Unless otherwise noted, amounts and disclosures throughout these notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of revenue recognition, the provision for income taxes, net realizable value of inventory, and fair value of the preferred investment option and contingent liabilities. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Cash and cash equivalents The Company considers any liquid investment with a stated maturity of three months or less at the date of purchase to be a cash equivalent. Cash and cash equivalents consist of cash on deposit with banks and money-market funds. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. Investments in debt and equity securities Investments in debt and equity securities are carried at fair value and classified as short-term investments. Unrealized gains and losses are included in accumulated other comprehensive income, which is reflected as a separate component of stockholder’s equity in the consolidated balance sheets. Gains and losses are recognized when realized in the consolidated statements of operations and comprehensive loss. Investment securities are reported as cash and cash equivalent, short-term investments or long-term investments in the consolidated balance sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. Other-than-temporary impairments on investments The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2023 and 2022, there was no impairment of the Company’s investments. Accounts receivable and other receivables Accounts receivable represents amounts owed to the Company from product sales, licenses, and royalties. Other receivables represent amounts owed to the Company for miscellaneous non-trade activities including the sale of property and equipment. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had $ 0 and $ 3,000 amounts reserved for doubtful accounts at December 31, 2023 and 2022, respectively, and the allowance activity during each of the years ended December 31, 2023 and 2022, was immaterial. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value . GoodWheat: Proprietary wheat plants are grown, producing seed and grain with a variety of improved nutritional qualities, including high levels of amylose, improved shelf life, and reduced gluten. The seed is used for subsequent plantings and the grain is either sold or used as an ingredient in the production of food products, which the Company refers to collectively as GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process harvested seed and grain, and costs to mill the grain into flour. Zola Coconut water : Inventories mainly consist of coconut water imported from Thailand, freight-in, supplies, and labor. The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat products and Zola Coconut water. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat products, seed and grain. Raw materials inventories consist primarily of GoodWheat seeds and in-transit Zola Coconut Water. Finished goods inventories consist primarily of GoodWheat products and Zola Coconut Water that are available for sale, as well as GoodWheat grain. Property and equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2 - 20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2 - 10 * *Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease. The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of fixed assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. Fair value of financial instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. Concentration of risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties. Customer concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of 2023 2022 Customer A — 57 Customer B 19 — Customers representing greater than 10% of total revenues were as follows (in percentages): For Year Ended 2023 2022 Customer B 10 — Customer C — 13 Customer D 15 — Stock-based compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 12 for additional information. Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2023 2022 Research and development $ 3 $ 75 Selling, general and administrative 714 1,031 Total stock-based compensation $ 717 $ 1,106 Income taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Net loss per share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses. Revenue recognition The Company derives its revenues from product sales, licensing agreements and royalty fees. Product revenues Product revenues consist primarily of GoodWheat, Zola and GLA products. We recognize revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers,” which generally occurs upon delivery. The Company's revenues fluctuate depending on the timing of shipments of product to our customers and are reported net of estimated chargebacks, returns and losses. License revenues License revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that the Company receives under the Company’s research and license agreements. The Company recognizes revenue generated from up-front, nonrefundable license fees upon execution of the agreement and recognizes annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees. Milestones typically consist of significant stages of development for the Company’s traits in a potential commercial product, such as achievement of specific technological targets, completion of field trials, filing with regulatory agencies, completion of the regulatory process, and commercial launch of a product containing the Company’s traits. Given the seasonality of agriculture and time required to progress from one milestone to the next, achievement of milestones is inherently uneven, and the Company’s license revenues are likely to fluctuate significantly from period to period. Royalty revenues Royalty revenues consist of amounts earned from the sale of commercial products that incorporate the Company's traits by third parties. Royalty revenues consist of a minimum annual royalty, offset by amounts earned from the sale of products. The Company recognizes the minimum annual royalty on a straight-line basis over the year, and the Company recognizes royalty revenue resulting from the sale of products when the third parties transfer control of the product to their customers, which generally occurs upon shipment. Royalty revenues can fluctuate depending on the timing of shipments of product by the third parties to their customers. Unearned revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement is not yet earned in accordance with the Company policies. Cost of revenues Cost of revenues primarily relates to the sale of GoodWheat and Zola products and consists of the cost of raw materials, including internal and third-party services costs related to procuring, processing, formulating, packaging and shipping our products, as well as in-licensing and royalty fees, any adjustments or write-downs to inventory or prepaid production costs. Research and development expenses Research and development expenses consist of costs incurred in the development and testing of the Company's products and other products in development incorporating the Company's traits. These expenses currently consist primarily of fees paid to product formulation consultants and are expensed as incurred. Additionally, the Company is required from time to time to make certain milestone payments in connection with the development of technologies in-licensed from third parties. The Company's research and development expenses may fluctuate from period to period. Change in the estimated fair value of common stock warrant and option liabilities Change in the estimated fair value of common stock warrant and option liabilities is comprised of the fair value remeasurement of liability classified common stock warrants and options. See Note 10.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 3. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Additionally, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 in April 2019 and ASU 2019-05, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief in May 2019. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. In November 2019, the FASB issued ASU No. 2019-10, which defers the effective date of ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted A SU No. 2016-13 on January 1, 2023 with an immaterial impact on the Company’s disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures. The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The new guidance is effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of this update on our segment disclosures in Note 17. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures. The amendments in this update require additional income tax disclosures primarily related to the rate reconciliation and income taxes paid. The new guidance is effective either prospectively or retrospectively, for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of this update on our income tax disclosures.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventory	Note 4. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of revenues and are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded inventory write-downs of $ 444,000 related to packaging materials, hemp seed and GoodWheat during the year ended December 31, 2023. The Company recorded write-downs of wheat, hemp seed and CBD oil inventories, as well as body care products of $ 2.5 million for the year ended December 31, 2022. Of inventory write-downs during the year ended December 31, 2022, $ 394,000 was related to the Radiance Beauty licensing agreement. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Company’s expenses in the period the write down is taken and materially affect the Company’s operating results. Inventories, net consist of the following (in thousands): December 31, December 31, Raw materials $ 484 $ 610 Goods in process 55 — Finished goods 4,773 2,478 Inventories $ 5,312 $ 3,088

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 5. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): As of December 31, 2023 2022 Laboratory equipment $ 273 $ 679 Software and computer equipment 349 383 Machinery and equipment 440 450 Furniture and fixtures 39 83 Vehicles 202 306 Leasehold improvements 1,590 1,590 Property and equipment, gross 2,893 3,491 Less accumulated depreciation and amortization ( 2,509 ) ( 2,811 ) Property and equipment, net $ 384 $ 680 Depreciation expense was $ 287,000 and $ 439,000 for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2022, there was $ 10,000 of construction in progress included in property and equipment that had not been placed into service and was not subject to depreciation. As of December 31, 2023, there was no construction in progress included in property and equipment. Property and equipment are considered assets held for sale when management approves and commits to a plan to dispose of a property or group of properties. The property and equipment held for sale prior to the sale date is separately presented, within current assets, on the consolidated balance sheet as assets held for sale. Property and equipment related to Archipelago, in the amount of $ 51,000 and $ 87,000 have been classified as assets held for sale, and are recorded at fair value as of December 31, 2023 and 2022, respectively. The fair value has been estimated using publicly available prices for some of the assets, and business partners' estimates for assets with prices not readily available, due to the relatively small size of the industry in which they can be used. During the year ended December 31, 2023, the Company sold property and equipment and realized a gain on sale of $ 40,000 recorded on the consolidated statements of operations and comprehensive loss, with proceed s of $ 115,000 . During the year ended December 31, 2022, management initiated the sale of property and equipment related to the Davis laboratory, Archipelago and Body Care. The Company completed the sale of such property and equipment with a net gain on sale of property and equipment in the amount of $ 314,000 recorded on the consolidated statements of operations and comprehensive loss during the year ended December 31, 2022. The proceeds related to the sale of property and equipment during the year ended December 31, 2022 were $ 920,000 . During the year ended December 31, 2022, the Company recorded write-downs of property and equipment of $ 530,000 , of which $ 320,000 was related to the Radiance Beauty licensing agreement. There were no such write-downs of property and equipment during the year ended December 31, 2023.

Investments and Fair Value Inst

Investments and Fair Value Instruments	12 Months Ended
	Dec. 31, 2023
Investments And Fair Value Instruments [Abstract]
Investments and Fair Value Instruments	Note 6. Investments and Fair Value Instruments Investments The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses are included in accumulated other comprehensive income, which is reflected as a separate component of stockholder’s equity in the consolidated balance sheets. Gains and losses are recognized when realized in the consolidated statements of operations and comprehensive loss. The following tables summarize the amortized cost and fair value of the investment securities portfolio at December 31, 2023 and 2022: (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2023 Cash equivalents: Money market funds $ 4,925 $ — $ — $ 4,925 Short-term investments: Treasury bills 5,023 101 — 5,124 Total Assets at Fair Value $ 9,948 $ 101 $ — $ 10,049 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2022 Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620 The Company did no t have any investment categories that were in a continuous unrealized loss position for more than twelve months as of December 31, 2023 and 2022. Fair Value Measurement The fair value of the investment securities at December 31, 2023 were as follows: Fair Value Measurements at December 31, 2023 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 4,925 $ — $ — $ 4,925 Short-term investments: Treasury bills 5,124 — — 5,124 Total Assets at Fair Value $ 10,049 $ — $ — $ 10,049 The fair value of the investment securities at December 31, 2022 were as follows: Fair Value Measurements at December 31, 2022 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2023 or 2022. The Company’s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable and other receivables, accounts payable and accrued liabilities. For short-term investments, accounts receivable and other receivables, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2023 and December 31, 2022 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah, Inc. ("Anawah") acquisition as described in Note 13, as well as preferred investment options related to the March 2023 Private Placement and August 2022 Registered Direct offerings discussed in Note 10. The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of December 31, 2023 and 2022, using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Company’s ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement. The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at December 31, 2023 and 2022: March 2023 Options - Series A & March 2023 Options - Series B August 2022 Options & August 2022 Placement Agent Options December 31, December 31, December 31, December 31, December 31, December 31, Remaining term (in years) 4.16 — 0.61 — 3.67 4.67 Expected volatility 91.7 % — 78.7 % — 90.5 % 106.2 % Risk-free interest rate 3.9 % — 5.2 % — 4.0 % 4.0 % Expected dividend yield 0 % — 0 % — 0 % 0 % The significant unobservable input used in the fair value measurement of the Company’s Level 3 warrant liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement. The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) March 2023 March 2023 March 2023 Placement Agent Options August 2022 August 2022 Contingent Total Balance as of December 31, 2022 $ — $ — $ — $ 767 $ 39 $ 2,000 $ 2,806 Initial recognition 4,324 2,274 212 — — — 6,810 Change in fair value and ( 3,316 ) ( 2,233 ) ( 166 ) ( 608 ) ( 36 ) — ( 6,359 ) Balance as of December 31, 2023 $ 1,008 $ 41 $ 46 $ 159 $ 3 $ 2,000 $ 3,257 Assets classified as held for sale are recorded at fair value as of December 31, 2023 and 2022. The Company has classified the fair value measurements as a Level 3 measurement in the fair value hierarchy as the fair value has been estimated using publicly available prices for some of the assets, and business partners' estimates for assets with prices not readily available, due to the relatively small size of the industry in which they can be used.

Consolidated Joint Venture

Consolidated Joint Venture	12 Months Ended
	Dec. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
Consolidated Joint Venture	Note 7. Consolidated Joint Venture In 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of December 31, 2023, the Company and Legacy hold 50.75 % and 49.25 % interests in Archipelago, respectively, and have made capital contributions to Archipelago of $ 3.1 million and $ 3.0 million, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $ 5,000 and $ 236,000 was recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2023 and 2022, respectively. Legacy’s equity interests are presented as non-controlling interests on the consolidated balance sheets. Refer to Note 2 for basis of presentation. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Note 8. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2023 2022 Accounts payable - trade $ 801 $ 905 Payroll and benefits 1,303 1,373 Inventory — 69 Royalty fees due to unrelated parties 4 6 Consulting — 8 Rent and utilities — 28 Audit and tax fees 218 99 Legal 40 69 Other 44 298 Total accounts payable and accrued expenses $ 2,410 $ 2,855

Collaborative Arrangements

Collaborative Arrangements	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangements	Note 9. Collaborative Arrangements In August 2017 , the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva AgriScience (“Corteva”) and involves a joint operating activity where both Arcadia and Corteva are active participants in the activities of the collaboration. Arcadia and Corteva participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development , which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

Equity Financing

Equity Financing	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Equity Financing	Note 10. Equity Financing March 2023 Private Placement In March 2023, the Company issued in a private placement offering (the “March 2023 Private Placement”) pursuant to a securities purchase agreement (“March 2023 Purchase Agreement”) (i) 165,500 shares of its common stock, (ii) pre-funded common stock purchase warrants (the “March 2023 Pre-Funded Warrants”) to purchase up to 500,834 shares of common stock, at an exercise price of $ 0.0001 per share, (iii) Series A preferred investment options (the “March 2023 Options - Series A") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $ 9.00 per share, and (iv) Series B preferred investment options (the “March 2023 Options - Series B”, and together with the March 2023 Options - Series A, the "March 2023 Options") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $ 9.00 per share, and raised total gross proceeds of $ 6.0 million. The March 2023 Private Placement closed on March 6, 2023. The March 2023 Pre-Funded Warrants became exercisable upon issuance and are exercisable until exercised in full. The March 2023 Options - Series A are exercisable at any time at the option of the holder and expire 5 years from the date of issuance. The March 2023 Options - Series B are exercisable at any time at the option of the holder and expire 1.5 years from the date of issuance. During the year ended December 31, 2023, 425,834 Pre-Funded Warrants were exercised. In connection with the March 2023 Private Placement, the Company entered into preferred investment option amendment agreements (the “Option Amendment Agreements”) with certain investors. Under the Option Amendment Agreements, the Company agreed to amend certain existing warrants and preferred investment options to purchase up to a total of 178,132 shares of common stock that were previously issued to the investors in September 2019, May 2020, July 2020, December 2020, January 2021 and August 2022, with exercise prices of $ 300.80 , $ 191.00 , $ 154.00 , $ 120.00 , $ 125.20 and $ 37.35 per share, respectively (the “Existing Warrants”). Under the Option Amendment Agreements, the Company agreed to lower the exercise price of the Existing Warrants to $ 9.00 per share. In addition, the Company granted to a placement agent preferred investment options to purchase a total of 33,317 shares of Common Stock (the “March 2023 Placement Agent Options”) that have an exercise price per share equal to $ 11.25 and a term of 5 years from the date of issuance. The re-pricing of the Existing Warrants resulted in an increase in fair value of $ 404,000 , of which $ 185,000 of the increase in fair value was related to the August 2022 liability classified options. The increase in fair value related to the re-pricing of Existing Warrants was recognized in Valuation Loss on March 2023 PIPE on the consolidated statements of operations and comprehensive loss. The March 2023 Options and March 2023 Placement Agent Options are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification. The Company utilized the Black-Scholes Model on March 6, 2023 with the following assumptions for the Series A Investment Options: volatility of 128.55 %, stock price of $ 7.61 and risk-free rate of 4.27 %. The following assumptions were utilized for the Series B Investment Options: volatility of 103.33 %, stock price of $ 7.61 and risk-free rate of 4.97 %. The estimated fair value of the liability classified March 2023 Options issued was $ 6.6 million. The estimated fair value of the common stock option liabilities was subsequently remeasured at December 31, 2023 with the changes recorded on the Company’s consolidated statements of operations and comprehensive loss. The estimated fair value of the common stock issued and March 2023 Pre-Funded Warrants was $ 5.1 million. The total estimated fair value of the common stock issued, March 2023 Pre-Funded Warrants and March 2023 Options as of March 6, 2023 exceeded the gross proceeds of the March 2023 Private Placement by $ 5.7 million and this amount was recognized in Valuation Loss on March 2023 PIPE on the consolidated statements of operations and comprehensive loss. The March 2023 Placement Agent Options were issued for services performed by the placement agent as part of the March 2023 Private Placement and were treated as offering costs. The value of the March 2023 Placement Agent Options was determined to be $ 212,000 , calculated using the Black-Scholes Model. The Company incurred additional offering costs totaling $ 548,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the March 2023 Private Placement. A total of $ 430,000 was allocated to the common stock option liabilities and expensed while the remaining $ 330,000 was allocated to the common stock and March 2023 Pre-Funded Warrants and offset to additional paid in capital. August 2022 Registered Direct Offering On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018 (“2018 Shelf Registration Statement”). On April 21, 2022, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on May 12, 2022 (“2022 Shelf Registration Statement”). Each of the 2018 Shelf Registration Statement and the 2022 Shelf Registration Statement allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having aggregate offering prices of up to $ 50.0 million. The Company ceased being able to use the 2018 Shelf Registration Statement after June 8, 2021, the three-year anniversary of its effective date. The 2022 Shelf Registration Statement may no longer be used after May 12, 2025, the three-year anniversary of its effective date. In August 2022, the Company entered into a securities purchase agreement (the “August 2022 Purchase Agreement”) pursuant to which it sold (i) 61,250 registered shares of its common stock, pursuant to the 2022 Shelf Registration Statement, (ii) pre-funded common stock purchase warrants (the “August 2022 Pre-Funded Warrants”) to purchase up to 56,813 shares of common stock, at an exercise price of $ 0.004 per share, which the August 2022 Pre-Funded Warrants were registered under the 2022 Shelf Registration Statement, and (iii) unregistered preferred investment options (the "August 2022 Options") to purchase up to 118,063 shares of common stock, at an exercise price of $ 37.35 per share, for total gross proceeds of $ 5.0 million (the “August 2022 Registered Direct Offering”). The August 2022 Registered Direct Offering closed on August 16, 2022 . The August 2022 Pre-Funded Warrants became exercisable upon issuance and were fully exercised during the year ended December 31, 2023. The August 2022 Options became exercisable upon issuance and expire 5 years after the date of issuance. In connection with the August 2022 Registered Direct Offering, the Company granted to a placement agent preferred investment options ("August 2022 Placement Agent Options") to purchase a total of 5,904 shares of common stock that have an exercise price per share equal to $ 52.80 and a term of five years . The August 2022 Options and August 2022 Placement Agent Options are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification. The Company utilized the Black-Scholes Model on August 16, 2022 with the following assumptions: volatility of 128.46 %, stock price of $ 37.60 , risk-free rate of 2.97 % and a term of 5 years. The estimated fair value of the common stock option liabilities was subsequently remeasured at December 31, 2023 with the changes recorded on the Company’s consolidated statements of operations and comprehensive loss. The August 2022 Placement Agent Options were issued for services performed by the placement agent as part of the August 2022 Registered Direct Offering and were treated as offering costs. The value of the August 2022 Placement Agent Options was determined to be $ 191,000 , calculated using the Black-Scholes Model. The Company incurred additional offering costs totaling $ 488,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the August 2022 Registered Direct Offering. The offering costs, inclusive of the August 2022 Placement Agent Options, totaled $ 679,000 and were allocated to the common stock option liabilities, the common stock and August 2022 Pre-Funded Warrants using their relative fair values. A total of $ 314,000 was allocated to the common stock option liabilities and expensed while the remaining $ 365,000 was allocated to the common stock and August 2022 Pre-Funded Warrants and offset to additional paid in capital.

Warrants and Options

Warrants and Options	12 Months Ended
	Dec. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Warrants and Options	Note 11. Warrants and Options Equity Classified Common Stock Warrants The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of December 31, 2023 and 2022, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at March 2023 Pre-Funded Warrants March 2023 perpetual $ — — — ( 425,834 ) 75,000 December 2022 Service and Performance Warrants (1) December 2022 5 years $ 11.20 — 1,000 — 1,000 October 2022 Service and Performance Warrants (1) October 2022 5 years $ 16.00 — 1,000 — 1,000 August 2022 Pre-Funded Warrants August 2022 perpetual $ — — 56,813 ( 56,813 ) — January 2021 Placement Agent Warrants January 2021 5.5 years $ 159.60 — 9,846 — 9,846 January 2021 Service and Performance Warrants (1)(3) January 2021 2 years $ 123.20 — 188 — — December 2020 Warrants (4) December 2020 5.5 years $ 9.0 0 — 16,367 — 16,367 December 2020 Warrants December 2020 5.5 years $ 120.00 — 49,100 — 49,100 December 2020 Placement Agent Warrants December 2020 5 years $ 152.80 — 3,274 — 3,274 July 2020 Warrants (4) July 2020 5.5 years $ 9.00 — 16,036 — 16,036 July 2020 Placement Agent Warrants July 2020 5.5 years $ 198.80 — 802 — 802 May 2020 Warrants (4) May 2020 5 years $ 9.00 — 9,946 — 9,946 May 2020 Warrants May 2020 5 years $ 191.20 — 24,863 — 24,863 May 2020 Placement Agent Warrants May 2020 5 years $ 245.20 — 1,741 — 1,741 March 2020 Service and Performance Warrants (1)(3) March 2020 3 years $ 100.00 — 459 — — September 2019 Placement Agent Warrants September 2019 5 years $ 379.20 — 1,649 — 1,649 June 2019 Placement Agent Warrants June 2019 5 years $ 251.60 — 1,862 — 1,862 April 2019 Service and Performance Warrants (1) April 2019 5 years $ 247.20 — 3,629 — 3,629 June 2018 Placement Agent Warrants (3) June 2018 5 years $ 502.80 — 1,741 — — March 2018 Placement Agent Warrants (3) March 2018 5 years $ 1,662.40 — 376 — — January 2021 Warrants (2)(4) January 2021 5.5 years $ 9.00 — 7,831 — 7,831 January 2021 Warrants (2) January 2021 5.5 years $ 125.20 — 90,629 — 90,629 September 2019 Warrants (2)(4) September 2019 5.5 years $ 9.00 — 9,892 — 9,892 September 2019 Warrants (2) September 2019 5.5 years $ 300.80 — 6,594 — 6,594 June 2019 Warrants (2) June 2019 5.5 years $ 200.00 — 10,896 — 10,896 March 2018 Warrants (2)(3) March 2018 5 years $ 429.20 — 16,036 — — Total — 342,570 ( 482,647 ) 341,957 (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and were adjusted to fair value at each balance sheet date. Upon adoption of ASU No. 2020-06 on January 1, 2022, all of the common stock warrant liabilities have been reclassified to equity classified common stock warrants, due to the elimination of the contingent cash payments as criteria for liability classification. (3) These warrants expired in the during the year ended December 31, 2023 . (4) These warrants were repriced as part of the March 2023 Private Placement offering. Liability Classified Preferred Investment Options The preferred investment options issued in connection with the March 2023 Private Placement and August 2022 Registered Direct offerings contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows: Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at March 2023 Options - Series A March 2023 5 years $ 9.00 — — — 666,334 March 2023 Options - Series B March 2023 1.5 years $ 9.00 — — — 666,334 March 2023 Placement Agent Options March 2023 5 years $ 11.25 — — — 33,317 August 2022 Options (1) August 2022 5 years $ 9.00 — 118,063 — 118,063 August 2022 Placement Agent Options August 2022 5 years $ 52.80 — 5,904 — 5,904 Total — 123,967 — 1,489,952 See Note 6 for the Black-Scholes option-pricing model and weighted-average assumptions used to estimate the fair value of the preferred investment options liabilities.

Stock-Based Compensation and Em

Stock-Based Compensation and Employee Stock Purchase Program	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation and Employee Stock Purchase Program	Note 12. Stock-Based Compensation and Employee Stock Purchase Program Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, there might be alternative vesting schedules, as approved by the Board. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested. In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 3,000 shares. On February 2, 2022, Stanley Jacot, Jr. was hired as the new president and chief executive officer of the Company. The Company granted Mr. Jacot an inducement stock option to purchase 7,902 shares of the Company’s common stock pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company has filed a registration statement on Form S-8 to register the issuance of shares upon exercise of this inducement stock option. The inducement options grants have been issued outside of the 2015 Plan, but are subject to the terms and conditions of the 2015 Plan. As of December 31, 2023, a total of 86,835 shares of common stock were reserved for issuance under the 2015 Plan, of which 15,226 shares of common stock are available for future grant. As of December 31, 2023, a total of 102 and 71,609 options were outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2022, a total of 103 and 51,421 options were outstanding under the 2006 and 2015 Plans, respectively. A total of 8,366 and 8,477 inducement options were outstanding as of December 31, 2023 and 2022, respectively. The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2021 35,554 $ 211.20 $ — Options granted 33,408 44.00 11,880 Options exercised — — — Options forfeited ( 6,658 ) 91.60 — Options expired ( 2,302 ) 644.80 — Outstanding — Balance at December 31, 2022 60,002 114.80 — Options granted 26,021 6.38 — Options exercised — — — Options forfeited ( 5,644 ) 29.58 39,062 Options expired ( 301 ) 121.05 — Outstanding — Balance at December 31, 2023 80,078 85.30 — Vested and expected to vest — December 31, 2023 74,608 89.85 — Exercisable —December 31, 2023 41,735 $ 139.82 $ — Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by its Board of Directors for each of the respective periods. As of December 31, 2023, there was $ 623,000 of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.1 years. In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected Term— The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards. Expected Volatility— The historical volatility data was computed using the daily closing prices for the Company’s shares during the equivalent period of the calculated expected term of the stock-based awards. Risk-Free Interest Rate— The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted. Expected Dividend— The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders. The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption: Year Ended December 31, Assumptions 2023 2022 Expected term (years) 7.06 6.40 Expected volatility 124 % 122 % Risk-free interest rate 3.61 % 2.61 % Expected dividend yield — — The weighted-average, estimated grant date fair value of employee stock options granted during the years ended December 31, 2023 and 2022 was $ 5.72 and $ 38.50 , respectively. The Company recognized $ 717,000 and $ 1.1 million of compensation expense for stock options awards for the years ended December 31, 2023 and 2022, respectively. Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15 % of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016 , the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of December 31, 2023 , the number of shares of common stock reserved for future issuance under the ESPP were 7,265 . The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of December 31, 2023 , 3,468 shares had been issued under the ESPP. The Company recorded $6 ,000 and $ 4,000 of ESPP related compensation expense for the years ended December 31, 2023 and 2022 , respectively.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13. Commitments and Contingencies Leases The Company leases office and laboratory space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years , including certain renewal options available to the Company at market rates. See Note 14. Legal Matters From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings. Contingent Liability Related to the Anawah Acquisition In June 2005 , the Company completed its agreement and plan of merger and reorganization with Anawah to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $ 5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. During 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $ 3.0 million. During 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of December 31, 2023, the Company continues to pursue or are otherwise liable for a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $ 2.0 million remains on the consolidated balance sheet as an other noncurrent liability. Contingent Liability Related to the ISI Acquisition In August 2020, the Company acquired by merger ISI. A portion of the purchase price consideration for the acquisition in the amount of $ 280,000 was to be recognized in two annual installments, each of up to 3,316 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The contingent consideration was measured and recorded at fair value. The contingent consideration liability was remeasured quarterly with changes in fair value recorded in the consolidated statements of operations and comprehensive loss. During 2022, the contingent consideration liability was fully written down as the probability of achievement of the 2022 revenue milestone was remote. Contracts The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2 % to 15 % of net revenue amounts as defined in the In-Licensing Agreements are or will be due. The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Lessee Disclosure [Abstract]
Leases	Note 14. Leases Operating Leases As of December 31, 2023, the Company leases office space in Dallas, Texas, Davis and Sacramento, California, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases the Davis office to third parties. In 2022, the Company terminated its lease for office space in Chesterfield, MO effective September 30, 2022. The original lease term was scheduled to expire in May 2024 . As a result, the Company paid $ 47,000 in early termination fees. In addition, the Company subleased the facility in Chatsworth, CA to Radiance Beauty as part of the licensing agreement beginning November 1, 2022 for the remainder of the lease term. During 2022, the Company entered into an agreement to lease office space in Dallas, Texas. The new lease commenced in July 2022. Some leases (the Dallas and Davis offices and a warehouse) include one or more options to renew , with renewal terms that can extend the lease term from one to six years . The exercise of lease renewal options is at the Company’s sole discretion. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification December 31, 2023 December 31, 2022 Assets Operating lease assets Right of use asset $ 792 $ 1,848 Total leased assets $ 792 $ 1,848 Liabilities Current - Operating Operating lease liability - current $ 852 $ 1,010 Noncurrent - Operating Operating lease liability - noncurrent 155 1,007 Total leased liabilities $ 1,007 $ 2,017 Lease Cost Classification For the For the Operating lease cost SG&A and R&D Expenses $ 763 $ 1,028 Short term lease cost SG&A and R&D Expenses 13 6 Sublease income (1) SG&A and R&D Expenses ( 450 ) ( 384 ) Net lease cost $ 326 $ 650 (1) Sublease income is recorded as a reduction to lease expense. Lease Term and Discount Rate December 31, 2023 December 31, 2022 Weighted-average remaining 2.3 2.4 Weighted-average discount rate 6 % 6 % The maturities of the operating lease liabilities as of December 31, 2023 are as follows (in thousands): Years Ending December 31, Amounts 2024 $ 886 2025 156 Total operating lease payments $ 1,042 Less: imputed interest 35 Total current and noncurrent operating lease liabilities $ 1,007

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2023 2022 Domestic $ ( 13,978 ) $ ( 15,598 ) Foreign — — Loss before income taxes $ ( 13,978 ) $ ( 15,598 ) The total income tax provision for the years ended December 31, 2023 and 2022 was expense of $ 8,000 and $ 14,000 , respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2023 2022 Current: Federal $ — $ — State ( 7 ) ( 13 ) Foreign ( 1 ) ( 1 ) Total current tax (expense) ( 8 ) ( 14 ) Deferred: Federal — — State — — Foreign — — Total deferred tax (expense) — — Total tax (expense) $ ( 8 ) $ ( 14 ) The Company operates in only one federal jurisdiction, the United States. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2023 2022 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefits 5.0 % 16.0 % Change in valuation allowance ( 26.6 )% ( 40.9 )% Derivative liability 9.8 % 4.1 % PIPE Transactions ( 9.8 )% — Contingent Consideration Release — 0.1 % Non-controlling interest — ( 0.3 )% Other 0.5 % ( 0.1 )% Income tax provision ( 0.1 )% ( 0.1 )% Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, net operating loss carryforwards (“NOLs”) and other tax credits. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 23,160 $ 19,654 Stock-based compensation 4,654 4,541 Accrued payroll and benefits 342 296 Research and development credits 16 16 Fixed asset basis difference 87 54 Inventory reserve 102 445 Charitable contributions 3 2 Income from partnerships 231 97 Lease liability 261 531 Other accounts receivable reserve 147 65 Amortized intangibles 755 819 Goodwill 358 393 Section 174 Capitalization 583 340 Total deferred tax assets 30,699 27,253 Deferred tax liabilities: Right of use asset ( 205 ) ( 486 ) Total deferred tax liabilities ( 205 ) ( 486 ) Less valuation allowance ( 30,494 ) ( 26,767 ) Net deferred tax assets $ — $ — Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been offset by a valuation allowance. The net valuation allowance increased by $ 3.7 million and $ 6.3 million during the years ended December 31, 2023 and 2022, respectively. At December 31, 2023 , the Company had federal and state NOLs aggregating approximately $ 94.1 million and $ 60.4 million, respectively. At December 31, 2023, the utilization of a portion of the federal NOLs is subject to an annual limitation under Section 382 of the Internal Revenue Code (IRC). Of the $ 230.5 million of federal NOLs available, approximately $ 136.4 million are expected to expire unutilized due to ownership changes as defined in IRC Section 382. If not utilized, the federal and state NOLs will begin to expire in 2024. IRC Section 382 may also limit NOLs generated after 2022 and in future years. The Company evaluates deferred tax assets, including the benefit from NOLs, to determine if a valuation allowance is required. Such evaluation is based on consideration of all available evidence using a “more likely than not” standard with significant weight being given to evidence that can be objectively verified. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses; forecasts of future profitability; the length of statutory carryforward periods; the Company’s experience with operating losses; and tax-planning alternatives. The significant piece of objective negative evidence evaluated was the cumulative loss incurred through the year ended December 31, 2023 . Given this evidence and the expectation to incur operating losses in the foreseeable future, a full valuation allowance has been recorded against the net deferred tax asset. The Company will continue to maintain a full valuation allowance against the entire amount of its net deferred tax asset, until such time as the Company has determined that the weight of the objectively verifiable positive evidence exceeds that of the negative evidence. Although the Company has established a full valuation allowance on its net deferred tax asset, for Federal tax losses before 2018 and for all state tax losses, it has not forfeited the right to carryforward tax losses up to 20 years and apply such tax losses against taxable income in such years, thereby reducing its future tax obligations. Federal tax losses generated in 2018 and later do not expire. The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2023 , the Company’s tax years for 2004 through 2022 are generally subject to examination by the tax authorities. The years are open back to 2004 to the extent the NOLs being carried forward were generated then. The Company had the following unrecognized tax benefits (in thousands), none of which, if recognized, would impact the Company’s effective tax rate: Year Ended December 31, 2023 2022 Unrecognized tax benefit beginning balance $ 16 $ 17 Increases for tax positions taken in prior years — — Decreases for tax positions taken in prior years — ( 1 ) Increases for tax positions taken in current years — — Settlements — — Unrecognized tax benefit ending balance $ 16 $ 16 The Company does not anticipate its total unrecognized tax benefits as of December 31, 2023 will significantly change due to settlement of examination or the expiration of statute of limitations during the next 12 months. The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals or other material deviation in this estimate over the next 12 months. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2023, the Company has no t recognized any interest and penalties related to uncertain tax positions. In February 2023, the Company received notification from the Internal Revenue Service that our Archipelago joint venture was selected for audit for the 2021 tax year. The Company received a preliminary summary of examination changes during November 2023, is currently awaiting the Notice of Proposed Partnership Adjustment, and plans to accept the adjustments. Accordingly, the Company has adjusted the tax disclosures to capture the anticipated impact of the proposed adjustments. The Company is currently not under audit for state purposes.

Retirement Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Retirement Benefits	Note 16. Retirement Benefits The Company has a 401(k) retirement plan (the “Plan”) available for participation by all regular full-time employees who have completed three months of service with the Company. The Company established the Plan in 2008. The Plan provides for a discretionary matching contribution equal to 50 % of the amount of the employee’s salary deduction, not to exceed 3 % of the salary per employee. Highly compensated employees are excluded from receiving any discretionary matching contribution. Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment. The Company has the option to make discretionary matching contributions. The Company did no t make discretionary matching contributions during the years ended December 31, 2023 and 2022 .

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment and Geographic Information	Note 17. Segment and Geographic Information Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company’s chief operating decision maker. Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2023 2022 United States $ 5,032 $ 6,298 Argentina — 862 India 7 7 Canada 291 194 Germany — 57 Total $ 5,330 $ 7,418

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Net Loss per Share	Note 18. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards, warrants and options. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. Dilutive securities are not included in the computation of net loss per share when the impact would be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Year Ended December 31, 2023 2022 Options to purchase common stock 80,078 60,002 Warrants to purchase common stock 266,957 285,757 Preferred investment options 1,489,952 123,967 Total 1,836,987 469,726

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 19. Related Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, one of the Company’s largest stockholders, and the JSF share common officers and directors. JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $ 58,000 and $ 48,000 as of December 31, 2023 and December 31, 2022 , respectively, and are included in the consolidated balance sheets as amounts due to related parties.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 20. Subsequent Events Management has evaluated subsequent events through March 28, 2024, the date that the financial statements were available to be issued.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Organization	Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California, and additional facilities in American Falls, Idaho. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based food and beverage products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The acquisition of the assets of Live Zola, LLC (“Zola”) added coconut water to the Company's portfolio of products. In May 2021, the Company's wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”), acquired the businesses of Eko, Lief, and Zola. The acquisition included Saavy Naturals™, a line of natural body care products, Soul Spring™, a CBD-infused botanical therapy brand in the natural category, and ProVault™, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively "body care brands"). Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. On July 8, 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased as of September 30, 2023. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 6) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $ 10.0 million on sales of Haab 4 soybeans (“HB4”). An additional $ 2.0 million in cash is to be paid to Arcadia upon Verdeca of achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for “food and feed”. During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $ 862,000 and a gain on sale of Verdeca of $ 1.1 million on the consolidated statements of operations and comprehensive loss. The Company received the full payment of $ 2.0 million as of December 31, 2023.
Reverse Stock Split	Reverse Stock Split In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock. On F ebruary 15, 2023, the Company’s stockholders approved the certificate of amendment to the Company’s certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented.
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2023, the Company had an accumulated deficit of $ 271.8 million, cash and cash equivalents of $ 6.5 million and short-term investments of $ 5.1 million. For the years ended December 31, 2023 and 2022, the Company had net losses of $ 14.0 million and $ 15.6 million, respectively, and net cash used in operations of $ 15.3 million and $ 14.0 million, respectively. The Company believes that its existing cash and cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition.
Discontinued Operations	Discontinued Operations In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased as of September 30, 2023. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets and the results of the discontinued operations as a separate component of loss on the consolidated statements of operations and comprehensive loss for all periods presented. Major classes of line items constituting the balance sheet of discontinued operations: (In thousands) December 31, 2023 December 31, 2022 Assets Accounts receivable and other receivables $ — $ 66 Inventories, net — current — 250 Prepaid expenses and other current assets — 14 Property and equipment, net — 24 Total assets $ — $ 354 Liabilities Accounts payable and accrued expenses $ — $ 26 Total liabilities $ — $ 26 Major classes of line items constituting net loss from discontinued operations: Year Ended December 31, 2023 2022 (In thousands) Product revenue $ 357 $ 2,537 Cost of revenues ( 314 ) ( 3,700 ) Impairment of intangible assets — ( 263 ) Impairment of property and equipment — ( 371 ) Selling, general and administrative ( 864 ) ( 3,011 ) Other income, net — 24 Net loss from discontinued operations $ ( 821 ) $ ( 4,784 ) The following table presents significant non-cash items of discontinued operations: Year Ended December 31, (In thousands) 2023 2022 Depreciation $ 24 $ 88 Impairment of intangible assets $ — $ 263 Write-down of inventories $ — $ 1,369 Impairment of property and equipment $ — $ 371 Accounts receivable and other receivables $ 66 $ 588 Inventories $ 250 $ ( 251 ) Prepaid expenses and other current assets $ 14 $ 132 Accounts payable and accrued expenses $ ( 26 ) $ ( 415 ) There were no other significant operating or investing non-cash items for the years ended December 31, 2023 and 2022.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 5,000 and $ 236,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2023 and 2022, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the consolidated balance sheets as of December 31, 2023 and 2022. Reclassifications Certain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former body care brands reported as discontinued operations, see “Discontinued Operations” section above. Unless otherwise noted, amounts and disclosures throughout these notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of revenue recognition, the provision for income taxes, net realizable value of inventory, and fair value of the preferred investment option and contingent liabilities. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents The Company considers any liquid investment with a stated maturity of three months or less at the date of purchase to be a cash equivalent. Cash and cash equivalents consist of cash on deposit with banks and money-market funds. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents.
Investments in debt and equity securities	Investments in debt and equity securities Investments in debt and equity securities are carried at fair value and classified as short-term investments. Unrealized gains and losses are included in accumulated other comprehensive income, which is reflected as a separate component of stockholder’s equity in the consolidated balance sheets. Gains and losses are recognized when realized in the consolidated statements of operations and comprehensive loss. Investment securities are reported as cash and cash equivalent, short-term investments or long-term investments in the consolidated balance sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date.
Other-than-temporary impairments on investments	Other-than-temporary impairments on investments The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2023 and 2022, there was no impairment of the Company’s investments.
Accounts receivable and other receivables	Accounts receivable and other receivables Accounts receivable represents amounts owed to the Company from product sales, licenses, and royalties. Other receivables represent amounts owed to the Company for miscellaneous non-trade activities including the sale of property and equipment. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had $ 0 and $ 3,000 amounts reserved for doubtful accounts at December 31, 2023 and 2022, respectively, and the allowance activity during each of the years ended December 31, 2023 and 2022, was immaterial.
Inventory	Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value . GoodWheat: Proprietary wheat plants are grown, producing seed and grain with a variety of improved nutritional qualities, including high levels of amylose, improved shelf life, and reduced gluten. The seed is used for subsequent plantings and the grain is either sold or used as an ingredient in the production of food products, which the Company refers to collectively as GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process harvested seed and grain, and costs to mill the grain into flour. Zola Coconut water : Inventories mainly consist of coconut water imported from Thailand, freight-in, supplies, and labor. The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat products and Zola Coconut water. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat products, seed and grain. Raw materials inventories consist primarily of GoodWheat seeds and in-transit Zola Coconut Water. Finished goods inventories consist primarily of GoodWheat products and Zola Coconut Water that are available for sale, as well as GoodWheat grain.
Property and equipment	Property and equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2 - 20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2 - 10 * *Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Fair value of financial instruments	Fair value of financial instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability.
Concentration of risk	Concentration of risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.
Customer concentration	Customer concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of 2023 2022 Customer A — 57 Customer B 19 — Customers representing greater than 10% of total revenues were as follows (in percentages): For Year Ended 2023 2022 Customer B 10 — Customer C — 13 Customer D 15 —
Stock-based compensation	Stock-based compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 12 for additional information. Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2023 2022 Research and development $ 3 $ 75 Selling, general and administrative 714 1,031 Total stock-based compensation $ 717 $ 1,106
Income taxes	Income taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Net loss per share	Net loss per share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.
Revenue recognition	Revenue recognition The Company derives its revenues from product sales, licensing agreements and royalty fees.
Unearned revenue	Unearned revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement is not yet earned in accordance with the Company policies.
Cost of product revenues	Cost of revenues Cost of revenues primarily relates to the sale of GoodWheat and Zola products and consists of the cost of raw materials, including internal and third-party services costs related to procuring, processing, formulating, packaging and shipping our products, as well as in-licensing and royalty fees, any adjustments or write-downs to inventory or prepaid production costs.
Research and development expenses	Research and development expenses Research and development expenses consist of costs incurred in the development and testing of the Company's products and other products in development incorporating the Company's traits. These expenses currently consist primarily of fees paid to product formulation consultants and are expensed as incurred. Additionally, the Company is required from time to time to make certain milestone payments in connection with the development of technologies in-licensed from third parties. The Company's research and development expenses may fluctuate from period to period.
Change in the estimated fair value of common stock warrant and option liabilities	Change in the estimated fair value of common stock warrant and option liabilities Change in the estimated fair value of common stock warrant and option liabilities is comprised of the fair value remeasurement of liability classified common stock warrants and options. See Note 10.
Product Revenues
Revenue recognition	Product revenues Product revenues consist primarily of GoodWheat, Zola and GLA products. We recognize revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers,” which generally occurs upon delivery. The Company's revenues fluctuate depending on the timing of shipments of product to our customers and are reported net of estimated chargebacks, returns and losses.
License Revenues
Revenue recognition	License revenues License revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that the Company receives under the Company’s research and license agreements. The Company recognizes revenue generated from up-front, nonrefundable license fees upon execution of the agreement and recognizes annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees. Milestones typically consist of significant stages of development for the Company’s traits in a potential commercial product, such as achievement of specific technological targets, completion of field trials, filing with regulatory agencies, completion of the regulatory process, and commercial launch of a product containing the Company’s traits. Given the seasonality of agriculture and time required to progress from one milestone to the next, achievement of milestones is inherently uneven, and the Company’s license revenues are likely to fluctuate significantly from period to period.
Royalty
Revenue recognition	Royalty revenues Royalty revenues consist of amounts earned from the sale of commercial products that incorporate the Company's traits by third parties. Royalty revenues consist of a minimum annual royalty, offset by amounts earned from the sale of products. The Company recognizes the minimum annual royalty on a straight-line basis over the year, and the Company recognizes royalty revenue resulting from the sale of products when the third parties transfer control of the product to their customers, which generally occurs upon shipment. Royalty revenues can fluctuate depending on the timing of shipments of product by the third parties to their customers.

Description of Business (Tables

Description of Business (Tables)	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Major Classes of Line Items Constituting Discontinued Operations	Major classes of line items constituting the balance sheet of discontinued operations: (In thousands) December 31, 2023 December 31, 2022 Assets Accounts receivable and other receivables $ — $ 66 Inventories, net — current — 250 Prepaid expenses and other current assets — 14 Property and equipment, net — 24 Total assets $ — $ 354 Liabilities Accounts payable and accrued expenses $ — $ 26 Total liabilities $ — $ 26 Major classes of line items constituting net loss from discontinued operations: Year Ended December 31, 2023 2022 (In thousands) Product revenue $ 357 $ 2,537 Cost of revenues ( 314 ) ( 3,700 ) Impairment of intangible assets — ( 263 ) Impairment of property and equipment — ( 371 ) Selling, general and administrative ( 864 ) ( 3,011 ) Other income, net — 24 Net loss from discontinued operations $ ( 821 ) $ ( 4,784 ) The following table presents significant non-cash items of discontinued operations: Year Ended December 31, (In thousands) 2023 2022 Depreciation $ 24 $ 88 Impairment of intangible assets $ — $ 263 Write-down of inventories $ — $ 1,369 Impairment of property and equipment $ — $ 371 Accounts receivable and other receivables $ 66 $ 588 Inventories $ 250 $ ( 251 ) Prepaid expenses and other current assets $ 14 $ 132 Accounts payable and accrued expenses $ ( 26 ) $ ( 415 ) There were no other significant operating or investing non-cash items for the years ended December 31, 2023 and 2022.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Average Estimated Useful Lives of Assets	Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2 - 20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2 - 10 * *Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net	Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2023 2022 Research and development $ 3 $ 75 Selling, general and administrative 714 1,031 Total stock-based compensation $ 717 $ 1,106
Schedule of Customers Representing Greater than 10% of Account Receivable and Total Revenue	Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of 2023 2022 Customer A — 57 Customer B 19 — Customers representing greater than 10% of total revenues were as follows (in percentages): For Year Ended 2023 2022 Customer B 10 — Customer C — 13 Customer D 15 —

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories, net consist of the following (in thousands): December 31, December 31, Raw materials $ 484 $ 610 Goods in process 55 — Finished goods 4,773 2,478 Inventories $ 5,312 $ 3,088

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): As of December 31, 2023 2022 Laboratory equipment $ 273 $ 679 Software and computer equipment 349 383 Machinery and equipment 440 450 Furniture and fixtures 39 83 Vehicles 202 306 Leasehold improvements 1,590 1,590 Property and equipment, gross 2,893 3,491 Less accumulated depreciation and amortization ( 2,509 ) ( 2,811 ) Property and equipment, net $ 384 $ 680

Investments and Fair Value In_2

Investments and Fair Value Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Investments And Fair Value Instruments [Abstract]
Summary of Amortized Cost and Fair Value of Investment Securities Portfolio	(Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2023 Cash equivalents: Money market funds $ 4,925 $ — $ — $ 4,925 Short-term investments: Treasury bills 5,023 101 — 5,124 Total Assets at Fair Value $ 9,948 $ 101 $ — $ 10,049 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2022 Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620
Summary of Fair Value of Investment Securities	The fair value of the investment securities at December 31, 2023 were as follows: Fair Value Measurements at December 31, 2023 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 4,925 $ — $ — $ 4,925 Short-term investments: Treasury bills 5,124 — — 5,124 Total Assets at Fair Value $ 10,049 $ — $ — $ 10,049 The fair value of the investment securities at December 31, 2022 were as follows: Fair Value Measurements at December 31, 2022 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620
Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model	The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at December 31, 2023 and 2022: March 2023 Options - Series A & March 2023 Options - Series B August 2022 Options & August 2022 Placement Agent Options December 31, December 31, December 31, December 31, December 31, December 31, Remaining term (in years) 4.16 — 0.61 — 3.67 4.67 Expected volatility 91.7 % — 78.7 % — 90.5 % 106.2 % Risk-free interest rate 3.9 % — 5.2 % — 4.0 % 4.0 % Expected dividend yield 0 % — 0 % — 0 % 0 %
Summary of Changes in Fair Value and Other Adjustments of Liabilities	The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) March 2023 March 2023 March 2023 Placement Agent Options August 2022 August 2022 Contingent Total Balance as of December 31, 2022 $ — $ — $ — $ 767 $ 39 $ 2,000 $ 2,806 Initial recognition 4,324 2,274 212 — — — 6,810 Change in fair value and ( 3,316 ) ( 2,233 ) ( 166 ) ( 608 ) ( 36 ) — ( 6,359 ) Balance as of December 31, 2023 $ 1,008 $ 41 $ 46 $ 159 $ 3 $ 2,000 $ 3,257

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2023 2022 Accounts payable - trade $ 801 $ 905 Payroll and benefits 1,303 1,373 Inventory — 69 Royalty fees due to unrelated parties 4 6 Consulting — 8 Rent and utilities — 28 Audit and tax fees 218 99 Legal 40 69 Other 44 298 Total accounts payable and accrued expenses $ 2,410 $ 2,855

Warrants and Options (Tables)

Warrants and Options (Tables)	12 Months Ended
	Dec. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Issued to Purchase Common Stock	The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of December 31, 2023 and 2022, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at March 2023 Pre-Funded Warrants March 2023 perpetual $ — — — ( 425,834 ) 75,000 December 2022 Service and Performance Warrants (1) December 2022 5 years $ 11.20 — 1,000 — 1,000 October 2022 Service and Performance Warrants (1) October 2022 5 years $ 16.00 — 1,000 — 1,000 August 2022 Pre-Funded Warrants August 2022 perpetual $ — — 56,813 ( 56,813 ) — January 2021 Placement Agent Warrants January 2021 5.5 years $ 159.60 — 9,846 — 9,846 January 2021 Service and Performance Warrants (1)(3) January 2021 2 years $ 123.20 — 188 — — December 2020 Warrants (4) December 2020 5.5 years $ 9.0 0 — 16,367 — 16,367 December 2020 Warrants December 2020 5.5 years $ 120.00 — 49,100 — 49,100 December 2020 Placement Agent Warrants December 2020 5 years $ 152.80 — 3,274 — 3,274 July 2020 Warrants (4) July 2020 5.5 years $ 9.00 — 16,036 — 16,036 July 2020 Placement Agent Warrants July 2020 5.5 years $ 198.80 — 802 — 802 May 2020 Warrants (4) May 2020 5 years $ 9.00 — 9,946 — 9,946 May 2020 Warrants May 2020 5 years $ 191.20 — 24,863 — 24,863 May 2020 Placement Agent Warrants May 2020 5 years $ 245.20 — 1,741 — 1,741 March 2020 Service and Performance Warrants (1)(3) March 2020 3 years $ 100.00 — 459 — — September 2019 Placement Agent Warrants September 2019 5 years $ 379.20 — 1,649 — 1,649 June 2019 Placement Agent Warrants June 2019 5 years $ 251.60 — 1,862 — 1,862 April 2019 Service and Performance Warrants (1) April 2019 5 years $ 247.20 — 3,629 — 3,629 June 2018 Placement Agent Warrants (3) June 2018 5 years $ 502.80 — 1,741 — — March 2018 Placement Agent Warrants (3) March 2018 5 years $ 1,662.40 — 376 — — January 2021 Warrants (2)(4) January 2021 5.5 years $ 9.00 — 7,831 — 7,831 January 2021 Warrants (2) January 2021 5.5 years $ 125.20 — 90,629 — 90,629 September 2019 Warrants (2)(4) September 2019 5.5 years $ 9.00 — 9,892 — 9,892 September 2019 Warrants (2) September 2019 5.5 years $ 300.80 — 6,594 — 6,594 June 2019 Warrants (2) June 2019 5.5 years $ 200.00 — 10,896 — 10,896 March 2018 Warrants (2)(3) March 2018 5 years $ 429.20 — 16,036 — — Total — 342,570 ( 482,647 ) 341,957 (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and were adjusted to fair value at each balance sheet date. Upon adoption of ASU No. 2020-06 on January 1, 2022, all of the common stock warrant liabilities have been reclassified to equity classified common stock warrants, due to the elimination of the contingent cash payments as criteria for liability classification. (3) These warrants expired in the during the year ended December 31, 2023 . (4) These warrants were repriced as part of the March 2023 Private Placement offering.
Summary of Key Terms and Activity of Liability Classified Preferred Investment Options	The key terms and activity of the liability classified preferred investment options are summarized as follows: Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at March 2023 Options - Series A March 2023 5 years $ 9.00 — — — 666,334 March 2023 Options - Series B March 2023 1.5 years $ 9.00 — — — 666,334 March 2023 Placement Agent Options March 2023 5 years $ 11.25 — — — 33,317 August 2022 Options (1) August 2022 5 years $ 9.00 — 118,063 — 118,063 August 2022 Placement Agent Options August 2022 5 years $ 52.80 — 5,904 — 5,904 Total — 123,967 — 1,489,952

Stock-Based Compensation and _2

Stock-Based Compensation and Employee Stock Purchase Program (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Activity Under Stock Incentive Plans	The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2021 35,554 $ 211.20 $ — Options granted 33,408 44.00 11,880 Options exercised — — — Options forfeited ( 6,658 ) 91.60 — Options expired ( 2,302 ) 644.80 — Outstanding — Balance at December 31, 2022 60,002 114.80 — Options granted 26,021 6.38 — Options exercised — — — Options forfeited ( 5,644 ) 29.58 39,062 Options expired ( 301 ) 121.05 — Outstanding — Balance at December 31, 2023 80,078 85.30 — Vested and expected to vest — December 31, 2023 74,608 89.85 — Exercisable —December 31, 2023 41,735 $ 139.82 $ —
Weighted-Average Fair Value Assumption of Stock Option Awards	The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption: Year Ended December 31, Assumptions 2023 2022 Expected term (years) 7.06 6.40 Expected volatility 124 % 122 % Risk-free interest rate 3.61 % 2.61 % Expected dividend yield — —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Lessee Disclosure [Abstract]
Schedule of Leases	The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification December 31, 2023 December 31, 2022 Assets Operating lease assets Right of use asset $ 792 $ 1,848 Total leased assets $ 792 $ 1,848 Liabilities Current - Operating Operating lease liability - current $ 852 $ 1,010 Noncurrent - Operating Operating lease liability - noncurrent 155 1,007 Total leased liabilities $ 1,007 $ 2,017 Lease Cost Classification For the For the Operating lease cost SG&A and R&D Expenses $ 763 $ 1,028 Short term lease cost SG&A and R&D Expenses 13 6 Sublease income (1) SG&A and R&D Expenses ( 450 ) ( 384 ) Net lease cost $ 326 $ 650 (1) Sublease income is recorded as a reduction to lease expense. Lease Term and Discount Rate December 31, 2023 December 31, 2022 Weighted-average remaining 2.3 2.4 Weighted-average discount rate 6 % 6 %
Schedule of Maturities of Operating Lease Liabilities	The maturities of the operating lease liabilities as of December 31, 2023 are as follows (in thousands): Years Ending December 31, Amounts 2024 $ 886 2025 156 Total operating lease payments $ 1,042 Less: imputed interest 35 Total current and noncurrent operating lease liabilities $ 1,007

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Components of Loss Before Income Taxes	The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2023 2022 Domestic $ ( 13,978 ) $ ( 15,598 ) Foreign — — Loss before income taxes $ ( 13,978 ) $ ( 15,598 )
Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes	The total income tax provision for the years ended December 31, 2023 and 2022 was expense of $ 8,000 and $ 14,000 , respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2023 2022 Current: Federal $ — $ — State ( 7 ) ( 13 ) Foreign ( 1 ) ( 1 ) Total current tax (expense) ( 8 ) ( 14 ) Deferred: Federal — — State — — Foreign — — Total deferred tax (expense) — — Total tax (expense) $ ( 8 ) $ ( 14 )
Reconciliation of the Statutory Federal Income Tax Rate	The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2023 2022 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefits 5.0 % 16.0 % Change in valuation allowance ( 26.6 )% ( 40.9 )% Derivative liability 9.8 % 4.1 % PIPE Transactions ( 9.8 )% — Contingent Consideration Release — 0.1 % Non-controlling interest — ( 0.3 )% Other 0.5 % ( 0.1 )% Income tax provision ( 0.1 )% ( 0.1 )%
Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 23,160 $ 19,654 Stock-based compensation 4,654 4,541 Accrued payroll and benefits 342 296 Research and development credits 16 16 Fixed asset basis difference 87 54 Inventory reserve 102 445 Charitable contributions 3 2 Income from partnerships 231 97 Lease liability 261 531 Other accounts receivable reserve 147 65 Amortized intangibles 755 819 Goodwill 358 393 Section 174 Capitalization 583 340 Total deferred tax assets 30,699 27,253 Deferred tax liabilities: Right of use asset ( 205 ) ( 486 ) Total deferred tax liabilities ( 205 ) ( 486 ) Less valuation allowance ( 30,494 ) ( 26,767 ) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits	The Company had the following unrecognized tax benefits (in thousands), none of which, if recognized, would impact the Company’s effective tax rate: Year Ended December 31, 2023 2022 Unrecognized tax benefit beginning balance $ 16 $ 17 Increases for tax positions taken in prior years — — Decreases for tax positions taken in prior years — ( 1 ) Increases for tax positions taken in current years — — Settlements — — Unrecognized tax benefit ending balance $ 16 $ 16

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Summary of Revenues Based on Location of Customers	Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2023 2022 United States $ 5,032 $ 6,298 Argentina — 862 India 7 7 Canada 291 194 Germany — 57 Total $ 5,330 $ 7,418

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Year Ended December 31, 2023 2022 Options to purchase common stock 80,078 60,002 Warrants to purchase common stock 266,957 285,757 Preferred investment options 1,489,952 123,967 Total 1,836,987 469,726

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2020	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Place of incorporation		Arizona
Year of incorporation		2002
Place of reincorporation		Delaware
Date of reincorporation		2015-03
Accumulated deficit		$ (271,840,000)	$ (257,859,000)
Cash and cash equivalents		6,518,000	20,644,000
Short-term investments		5,124,000	0
Net loss		(13,986,000)	(15,612,000)
Net cash used in operations		$ (15,294,000)	(13,977,000)
Reverse stock split		In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock.
Additional shares of common stock of reverse stock split		19,118
License revenue		$ 5,330,000	7,418,000
Gain on sale of Verdeca		0	1,138,000
Payment received on accounts and other receivable		0	569,000
Verdeca LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gain on sale of Verdeca			1,100,000
Bioceres Crop Solutions [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue			$ 862,000
Bioceres Crop Solutions [Member] | Verdeca LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional cash receivable from sale of interest in joint venture	$ 2,000,000
Payment received on accounts and other receivable		$ 2,000,000
Bioceres Crop Solutions [Member] | Maximum [Member] | Verdeca LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash shares and royalty receivable	$ 10,000,000

Description of Business - Summa

Description of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations (Details) - Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] - Discontinued Operations [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Accounts receivable and other receivables	$ 0	$ 66
Inventories, net - current	0	250
Prepaid expenses and other current assets	0	14
Property and equipment, net	0	24
Total assets	0	354
Liabilities
Accounts payable and accrued expenses	0	26
Total liabilities	$ 0	$ 26

Description of Business - Sum_2

Description of Business - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of intangible assets	$ 0	$ (404)
Impairment of property and equipment	0	(530)
Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] | Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cost of revenues	(314)	(3,700)
Impairment of intangible assets	0	(263)
Impairment of property and equipment	0	(371)
Selling, general and administrative	(864)	(3,011)
Other income, net	0	24
Net loss from discontinued operations	(821)	(4,784)
Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] | Discontinued Operations [Member] | Product
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ 357	$ 2,537

Description of Business - Signi

Description of Business - Significant Non-cash Items of Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Impairment of intangible assets	$ 0	$ 404
Impairment of property and equipment	0	530
Changes in operating assets and liabilities:
Inventories	(2,419)	1,118
Prepaid expenses and other current assets	1	91
Accounts payable and accrued expenses	(522)	(757)
Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] | Discontinued Operations [Member]
Operating activities
Depreciation	24	88
Impairment of intangible assets	0	263
Write-down of inventories	0	1,369
Impairment of property and equipment	0	371
Changes in operating assets and liabilities:
Accounts receivable and other receivables	66	588
Inventories	250	(251)
Prepaid expenses and other current assets	14	132
Accounts payable and accrued expenses	$ (26)	$ (415)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Line Items]
Net loss attributable to noncontrolling interest	$ 5,000	$ 236,000
Reserved for doubtful accounts	0	3,000
Impairment of intangible assets	0	141,000
Limagrain Cereal Seeds LLC [Member]
Accounting Policies [Line Items]
Impairment of equity method investments	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Average Estimated Useful Lives of Assets (Detail)	Dec. 31, 2023
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Machinery and equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Machinery and equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	20 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	7 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold improvements [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Leasehold improvements [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Customers Representing Greater than 10% of Account Receivable and Total Revenue (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable [Member] | Customer A
Concentration Risk [Line Items]
Concentration risk percentage		57%
Accounts Receivable [Member] | Customer B
Concentration Risk [Line Items]
Concentration risk percentage	19%
Total Revenue [Member] | Customer B
Concentration Risk [Line Items]
Concentration risk percentage	10%
Total Revenue [Member] | Customer C
Concentration Risk [Line Items]
Concentration risk percentage		13%
Total Revenue [Member] | Customer D
Concentration Risk [Line Items]
Concentration risk percentage	15%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 717	$ 1,106
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	3	75
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 714	$ 1,031

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Detail) - Accounting Standards Update 2016-13 [Member]	Jan. 01, 2023
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2023
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Inventory [Line Items]
Write-down of inventories	$ 444,000	$ 2,471,000
Radiance Beauty Licensing Agreement [Member]
Inventory [Line Items]
Write-down of inventories		$ 394,000

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 484	$ 610
Goods in process	55	0
Finished goods	4,773	2,478
Inventories	$ 5,312	$ 3,088

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,893	$ 3,491
Less accumulated depreciation and amortization	(2,509)	(2,811)
Property and equipment, net	384	680
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	273	679
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	349	383
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	440	450
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	39	83
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	202	306
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,590	$ 1,590

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Depreciation expense	$ 287,000	$ 439,000
Property and equipment, gross	2,893,000	3,491,000
Gain on sale of property and equipment	40,000	314,000
Proceeds from sale of property and equipment	115,000	920,000
Property and equipment classified as assets held for sale, fair value	51,000	87,000
Impairments of property and equipment		530,000
Radiance Beauty Licensing Agreement [Member]
Property Plant And Equipment [Line Items]
Impairments of property and equipment		320,000
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 0	$ 10,000

Investments and Fair Value In_3

Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 9,948	$ 18,620
Unrealized Gains	101	0
Unrealized Losses	0	0
Estimated Fair Value	10,049	18,620
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	4,925	18,620
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	4,925	$ 18,620
Short-term Investments [Member] | Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	5,023
Unrealized Gains	101
Unrealized Losses	0
Estimated Fair Value	$ 5,124

Investments and Fair Value In_4

Investments and Fair Value Instruments - Additional Information (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0	$ 0

Investments and Fair Value In_5

Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets at Fair Value
Total Assets at Fair Value	$ 10,049	$ 18,620
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	4,925	18,620
Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 5,124
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	$ 10,049	18,620
Level 1 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	4,925	18,620
Level 1 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 5,124
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	$ 0	0
Level 2 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 2 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 0
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	$ 0	0
Level 3 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	$ 0
Level 3 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 0
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]

Investments and Fair Value In_6

Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Level 3 [Member]	Dec. 31, 2023	Dec. 31, 2022
Remaining Term [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	4 years 1 month 28 days	0 years
Remaining Term [Member] | March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	7 months 9 days	0 years
Remaining Term [Member] | August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	3 years 8 months 1 day	4 years 8 months 1 day
Expected Volatility [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	91.7	0
Expected Volatility [Member] | March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	78.7	0
Expected Volatility [Member] | August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	90.5	106.2
Risk-Free Interest Rate [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	3.9	0
Risk-Free Interest Rate [Member] | March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	5.2	0
Risk-Free Interest Rate [Member] | August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	4	4
Expected Dividend Yield [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	0
Expected Dividend Yield [Member] | March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	0
Expected Dividend Yield [Member] | August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	0

Investments and Fair Value In_7

Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Liabilities (Detail) - Level 3 [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 2,806
Initial recognition	6,810
Change in fair value and other adjustments	(6,359)
Ending Balance	3,257
March 2023 Options - Series A [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	4,324
Change in fair value and other adjustments	(3,316)
Ending Balance	1,008
March 2023 Options - Series B [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	2,274
Change in fair value and other adjustments	(2,233)
Ending Balance	41
March 2023 Placement Agent Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	212
Change in fair value and other adjustments	(166)
Ending Balance	46
August 2022 Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	767
Initial recognition	0
Change in fair value and other adjustments	(608)
Ending Balance	159
August 2022 Placement Agent Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	39
Initial recognition	0
Change in fair value and other adjustments	(36)
Ending Balance	3
Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,000
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	$ 2,000

Arcadia Wellness Acquisition -

Arcadia Wellness Acquisition - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Total revenues	$ 5,330,000	$ 7,418,000
Net loss attributable to common stockholders	(13,981,000)	(15,376,000)
Inventories written down	444,000	2,471,000
Impairments of property and equipment		530,000
Impairment of intangible assets	$ 0	141,000
Radiance Beauty Licensing Agreement [Member]
Business Acquisition [Line Items]
Inventories written down		$ 394,000

Arcadia Wellness Acquisition _2

Arcadia Wellness Acquisition - Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Weighted average shares - Basic	1,236,934	599,389
Weighted average shares - Diluted	1,236,934	599,389

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Parenthetical) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 0	$ 141

Consolidated Joint Venture - Ad

Consolidated Joint Venture - Additional Information (Detail)		12 Months Ended
	Aug. 09, 2019 Individual	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Schedule Of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest		$ 5,000	$ 236,000
Archipelago Ventures Hawaii, LLC [Member] | Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		50.75%
Capital contributions		$ 3,100,000
Archipelago Ventures Hawaii, LLC [Member] | Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		49.25%
Capital contributions		$ 3,000,000

Verdeca-BIOX Transactions - Add

Verdeca-BIOX Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2020	Dec. 31, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Fixed consideration allocated to sale of membership interest		$ 569,000	$ 569,000
Gain on sale of membership interests in Verdeca		0	1,138,000
Inventory contributed		1,958,000	2,321,000
Revenues		5,330,000	7,418,000
Proceeds from sale of Verdeca in accounts receivable and other receivables		0	569,000
Remaining accounts receivable and other receivables		514,000	1,221,000
License
Variable Interest Entity [Line Items]
Revenues		17,000	879,000
Bioceres Crop Solutions [Member]
Variable Interest Entity [Line Items]
Revenues			862,000
Verdeca LLC [Member]
Variable Interest Entity [Line Items]
Gain on sale of membership interests in Verdeca			$ 1,100,000
Verdeca LLC [Member] | Bioceres Crop Solutions [Member]
Variable Interest Entity [Line Items]
Additional cash receivable from sale of interest in joint venture	$ 2,000,000
Proceeds from sale of Verdeca in accounts receivable and other receivables		$ 2,000,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable - trade	$ 801	$ 905
Payroll and benefits	1,303	1,373
Inventory	0	69
Royalty fees due to unrelated parties	4	6
Consulting	0	8
Rent and utilities	0	28
Audit and tax fees	218	99
Legal	40	69
Other	44	298
Total accounts payable and accrued expenses	$ 2,410	$ 2,855

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Equity Financing - Additional I

Equity Financing - Additional Information (Detail) - USD ($)

1 Months Ended

12 Months Ended

Mar. 06, 2023

Aug. 16, 2022

Mar. 31, 2023

Aug. 31, 2022

Dec. 31, 2023

Dec. 31, 2022

Jun. 30, 2023

Jan. 31, 2021

Dec. 31, 2020

Jul. 31, 2020

May 31, 2020

Sep. 30, 2019

Class Of Warrant Or Right [Line Items]

Stock price

$ 3.88

Exercised during the year

(482,647)

0

Maximum [Member]

Class Of Warrant Or Right [Line Items]

Proceeds from issuance, aggregate offering prices

$ 50,000,000

Common Stock and Pre-Funded Warrants [Member]

Class Of Warrant Or Right [Line Items]

Remaining offering costs allocated to common stock and offset to additional paid in capital

$ 330,000

$ 365,000

August 2022 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

61,250

Offering closing period

Aug. 16, 2022

August 2022 Purchase Agreement [Member] | Pre Funded Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

56,813

Warrants issued, exercise price

$ 0.004

August 2022 Purchase Agreement [Member] | Preferred Investment Options [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

118,063

Exercise price

$ 37.35

Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE

$ 5,000,000

Warrants expiration period

5 years

March 2023 Placement Agent Options [Member]

Class Of Warrant Or Right [Line Items]

Issuance costs allocated to liability preferred options

$ 430,000

March 2023 Options and March 2023 Placement Agent Options [Member]

Class Of Warrant Or Right [Line Items]

Expected volatility

128.55%

Stock price

$ 7.61

Risk-free interest rate

4.27%

March 2023 Options and March 2023 Placement Agent Options [Member] | Series B Preferred Investment Options [Member]

Class Of Warrant Or Right [Line Items]

Expected volatility

103.33%

Stock price

$ 7.61

Risk-free interest rate

4.97%

March 2023 Options [Member]

Class Of Warrant Or Right [Line Items]

Estimated Fair Value of Liability Options

$ 6,600,000

August 2022 Options & August 2022 Placement Agent Options [Member]

Class Of Warrant Or Right [Line Items]

Expected volatility

128.46%

Stock price

$ 37.6

Risk-free interest rate

2.97%

Expected term

5 years

August 2022 Placement Agent Options [Member]

Class Of Warrant Or Right [Line Items]

Fair value assumptions, value

$ 191,000

Offering costs

488,000

Issuance costs allocated to liability preferred options

314,000

August 2022 Placement Agent Options [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Offering costs

$ 679,000

August 2022 Placement Agent Options [Member] | August 2022 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

5,904

Warrants issued, exercise price

$ 52.8

Warrant, exercisable term

5 years

March 2023 Private Placement [Member] | March 2023 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

165,500

Offering costs

$ 548,000

March 2023 Private Placement [Member] | March 2023 Purchase Agreement [Member] | Pre Funded Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

500,834

Warrants issued, exercise price

$ 0.0001

Exercised during the year

425,834

March 2023 Private Placement [Member] | March 2023 Purchase Agreement [Member] | Common Stock and Pre-Funded Warrants [Member]

Class Of Warrant Or Right [Line Items]

Fair value of common stock and pre-funded warrants

5,100,000

March 2023 Private Placement [Member] | Series A Preferred Investment Options [Member] | March 2023 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

666,334

Exercise price

$ 9

Options expiration period

5 years

March 2023 Private Placement [Member] | Series A and B Preferred Investment Options [Member] | March 2023 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

666,334

Exercise price

$ 9

Proceeds from issuance of common stock and warrants gross

$ 6,000,000

March 2023 Private Placement [Member] | Series B Preferred Investment Options [Member] | March 2023 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Options expiration period

1 year 6 months

March 2023 Private Placement [Member] | March 2023 Placement Agent Options [Member] | Preferred Investment Options [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

33,317

March 2023 Private Placement [Member] | March 2023 Placement Agent Options [Member] | March 2023 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Common stock options issued to placement agent and included in offering costs

212,000

March 2023 Private Placement [Member] | March 2023 Placement Agent Options [Member] | March 2023 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant and option modifications included in Valuation loss on March 2023 PIPE

404,000

March 2023 Private Placement [Member] | March 2023 Options [Member] | March 2023 Purchase Agreement [Member] | Common Stock and Pre-Funded Warrants [Member]

Class Of Warrant Or Right [Line Items]

Estimated fair value, loss

$ 5,700,000

March 2023 Private Placement [Member] | August 2022 Placement Agent Options [Member] | August 2022 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant and option modifications included in Valuation loss on March 2023 PIPE

$ 185,000

March 2023 Private Placement [Member] | Option Amendment Agreements [Member] | Preferred Investment Options [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

178,132

March 2023 Private Placement [Member] | Option Amendment Agreements [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrants issued, exercise price

$ 9

$ 37.35

$ 125.2

$ 120

$ 154

$ 191

$ 300.8

March 2023 Private Placement [Member] | Option Amendment Agreements [Member] | March 2023 Placement Agent Options [Member]

Class Of Warrant Or Right [Line Items]

Exercise price

$ 11.25

Warrant, exercisable term

5 years

Warrants and Options - Summary

Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Class Of Warrant Or Right [Line Items]
Exercised during the year	(482,647)	0
Outstanding	341,957	342,570
March 2023 Pre Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2023-03
Term	perpetual
Exercise Price Per Share	$ 0
Exercised during the year	(425,834)	0
Outstanding	75,000	0
December 2022 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-12
Term	5 years
Exercise Price Per Share	$ 11.2
Exercised during the year	0	0
Outstanding	1,000	1,000
October 2022 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-10
Term	5 years
Exercise Price Per Share	$ 16
Exercised during the year	0	0
Outstanding	1,000	1,000
August 2022 Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-08
Term	perpetual
Exercise Price Per Share	$ 0
Exercised during the year	(56,813)	0
Outstanding	0	56,813
January 2021 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 159.60
Exercised during the year	0	0
Outstanding	9,846	9,846
January 2021 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	2 years
Exercise Price Per Share	$ 123.20
Exercised during the year	0	0
Outstanding	0	188
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	16,367	16,367
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 120
Exercised during the year	0	0
Outstanding	49,100	49,100
December 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years
Exercise Price Per Share	$ 152.80
Exercised during the year	0	0
Outstanding	3,274	3,274
July 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	16,036	16,036
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 198.80
Exercised during the year	0	0
Outstanding	802	802
May 2020 Warrants Private Placement Offering [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	9,946	9,946
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 191.20
Exercised during the year	0	0
Outstanding	24,863	24,863
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 245.20
Exercised during the year	0	0
Outstanding	1,741	1,741
March 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-03
Term	3 years
Exercise Price Per Share	$ 100
Exercised during the year	0	0
Outstanding	0	459
September 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years
Exercise Price Per Share	$ 379.20
Exercised during the year	0	0
Outstanding	1,649	1,649
June 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years
Exercise Price Per Share	$ 251.60
Exercised during the year	0	0
Outstanding	1,862	1,862
April 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-04
Term	5 years
Exercise Price Per Share	$ 247.20
Exercised during the year	0	0
Outstanding	3,629	3,629
June 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years
Exercise Price Per Share	$ 502.80
Exercised during the year	0	0
Outstanding	0	1,741
March 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 1,662.4
Exercised during the year	0	0
Outstanding	0	376
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	7,831	7,831
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 125.2
Exercised during the year	0	0
Outstanding	90,629	90,629
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	9,892	9,892
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 300.8
Exercised during the year	0	0
Outstanding	6,594	6,594
June 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years 6 months
Exercise Price Per Share	$ 200
Exercised during the year	0	0
Outstanding	10,896	10,896
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 429.2
Exercised during the year	0	0
Outstanding	0	16,036

Warrants and Options - Summar_2

Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2023
January 2021 Service and Performance Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants expiration date	Dec. 31, 2023
March 2020 Service and Performance Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants expiration date	Dec. 31, 2023
March 2018 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants expiration date	Dec. 31, 2023
March 2018 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants expiration date	Dec. 31, 2023

Warrants and Options - Summar_3

Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
March 2023 Options - Series A [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2023-03
Term	5 years
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	666,334	0
March 2023 Options - Series B [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2023-03
Term	1 year 6 months
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	666,334	0
March 2023 Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2023-03
Term	5 years
Exercise Price Per Share	$ 11.25
Exercised during the year	0	0
Outstanding	33,317	0
August 2022 Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise Price Per Share	$ 9
Exercised during the year	0	0
Outstanding	118,063	118,063
August 2022 Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise Price Per Share	$ 52.8
Exercised during the year	0	0
Outstanding	5,904	5,904
March 2023, August 2022 Options and Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercised during the year	0	0
Outstanding	1,489,952	123,967

Stock-Based Compensation and _3

Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)				1 Months Ended	12 Months Ended
	Feb. 02, 2022 shares	May 20, 2015 shares	May 14, 2015	Jun. 30, 2019 shares	Dec. 31, 2023 USD ($) IncentivePlan $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | IncentivePlan					2
Shares Subject to Outstanding, Options granted					26,021	33,408
Total number of options outstanding					80,078	60,002	35,554
Intrinsic value of options exercisable | $					$ 0	$ 0
Unrecognized compensation cost related to unvested stock-based compensation grants | $					$ 623,000
Weighted-average remaining recognition period					2 years 1 month 6 days
Stock-based compensation | $					$ 717,000	$ 1,106,000
Weighted-average estimated grant-date fair value of stock options granted | $ / shares					$ 5.72	$ 38.5
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan					7,265
Stock-based compensation | $					$ 0	$ 4,000
Percentage in payroll deductions to acquire shares of common stock			15%
Purchase plan offering period			6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage			85%
Issuance of common stock pursuant to employee stock purchase plan					3,468
First offering period, start date			May 14, 2015
First offering period, end date			Feb. 01, 2016
Inducement Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of options outstanding					8,366	8,477
Inducement Stock Option [Member] | Stanley Jacot, Jr. [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Subject to Outstanding, Options granted	7,902
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan					The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan		3,860			86,835
Options vesting period		4 years
Additional shares authorized for issuance under the plan				3,000
Common stock available for future grant					15,226
Total number of options outstanding					71,609	51,421
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan		259
Total number of options outstanding					102	103
Maximum [Member] | 2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period		10 years

Stock-Based Compensation and _4

Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Shares Subject to Outstanding, Beginning Balance	60,002	35,554
Shares Subject to Outstanding, Options granted	26,021	33,408
Shares Subject to Outstanding, Options exercised	0	0
Shares Subject to Outstanding, Options Forfeited	(5,644)	(6,658)
Shares Subject to Outstanding, Options Expired	(301)	(2,302)
Shares Subject to Outstanding, Ending Balance	80,078	60,002
Shares Subject to Outstanding, Vested and expected to vest	74,608
Shares Subject to Outstanding, Exercisable	41,735
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 114.8	$ 211.2
Weighted-Average Exercise Price Per Share, Options granted	6.38	44
Weighted-Average Exercise Price Per Share, Options exercised	0	0
Weighted-Average Exercise Price Per Share, Options forfeited	29.58	91.6
Weighted-Average Exercise Price Per Share, Options expired	121.05	644.8
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	85.3	$ 114.8
Weighted Average Exercise Price Per Share, Vested and expected to vest	89.85
Weighted Average Exercise Price Per Share, Exercisable	$ 139.82
Aggregate Intrinsic Value, Beginning Balance	$ 0	$ 0
Aggregate Intrinsic Value, Options Granted	0	11,880
Aggregate Intrinsic Value, Options Exercised	0	0
Aggregate Intrinsic Value, Options Forfeited	39,062	0
Aggregate Intrinsic Value, Options Expired	0	0
Aggregate Intrinsic Value, Ending Balance	0	$ 0
Aggregate Intrinsic Value, Vested and expected to vest	0
Aggregate Intrinsic Value, Exercisable	$ 0

Stock-Based Compensation and _5

Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	7 years 21 days	6 years 4 months 24 days
Expected volatility	124%	122%
Risk-free interest rate	3.61%	2.61%
Expected dividend yield	0%	0%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Aug. 31, 2020 USD ($) Installment shares	Dec. 31, 2023 USD ($)	Dec. 31, 2010 USD ($) Program	Dec. 31, 2022 USD ($)	Jun. 30, 2005 USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,000,000		$ 2,000,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability			$ 3,000,000		$ 5,000,000
Date of merger and reorganization		Jun. 30, 2005
Restructuring activities, description		2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased | Program			3
Number of development programs | Program			6
Other noncurrent liability		$ 2,000,000
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Remaining amount paid in multiple installments	$ 280,000
Industrial Seed Innovations [Member] | Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable | Installment	2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		2%
Minimum [Member] | Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		15%
Maximum [Member] | Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years
Maximum [Member] | Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	3,316

Leases - Additional Information

Leases - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2023 USD ($)
Lessee Lease Description [Line Items]
Operating lease term, expiration	2024-05
Early termination fees	$ 47,000
Existence of option to extend	true
Lease option to extend, description	Some leases (the Dallas and Davis offices and a warehouse) include one or more options to renew, with renewal terms that can extend the lease term from one to six years
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Assets
Operating lease assets	$ 792	$ 1,848
Total leased assets	792	1,848
Liabilities
Current - Operating	852	1,010
Noncurrent - Operating	155	1,007
Total leased liabilities	1,007	2,017
Lease Cost
Net lease cost	$ 326	$ 650
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	2 years 3 months 18 days	2 years 4 months 24 days
Weighted-average discount rate	6%	6%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 763	$ 1,028
Short term lease cost	13	6
Sublease income	$ (450)	$ (384)

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Lessee Disclosure [Abstract]
2024	$ 886
2025	156
Total operating lease payments	1,042
Less: imputed interest	35
Operating Lease, Liability	$ 1,007	$ 2,017

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Domestic	$ (13,978)	$ (15,598)
Foreign	0	0
Net loss from continuing operations before income taxes	$ (13,978)	$ (15,598)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Income Tax [Line Items]
Income tax expense	$ 8,000	$ 14,000
Increase (decrease) in net valuation allowance	$ 3,700,000	$ 6,300,000
Operating loss carryforwards limitations on use	it has not forfeited the right to carryforward tax losses up to 20 years
Tax years subject to examination to extent of NOLs being carried forward	2004
Recognized any interest and penalties related to uncertain tax positions	$ 0
Maximum [Member]
Schedule Of Income Tax [Line Items]
Right to carryforward tax losses, period	20 years
Tax year subject to examination by the tax authorities	2022
Minimum [Member]
Schedule Of Income Tax [Line Items]
Tax year subject to examination by the tax authorities	2004
Federal [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 94,100,000
Operating loss carryforward	230,500,000
Operating loss carryforward expected to be unavailable	136,400,000
State [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 60,400,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 0	$ 0
State	(7,000)	(13,000)
Foreign	(1,000)	(1,000)
Total current tax (expense)	(8,000)	(14,000)
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total deferred tax (expense)	0	0
Total tax (expense)	$ (8,000)	$ (14,000)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate	21%	21%
State taxes, net of federal benefits	5%	16%
Change in valuation allowance	(26.60%)	(40.90%)
Derivative liability	9.80%	4.10%
PIPE Transactions	(9.80%)	0%
Contingent Consideration Release	0%	0.10%
Non-controlling Interest	0%	(0.30%)
Other	0.50%	(0.10%)
Income tax provision	(0.10%)	(0.10%)

Income Taxes - Summary of Compa

Income Taxes - Summary of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carryforwards	$ 23,160	$ 19,654
Stock-based compensation	4,654	4,541
Accrued payroll and benefits	342	296
Research and development credits	16	16
Fixed asset basis difference	87	54
Inventory reserve	102	445
Charitable contributions	3	2
Income from partnerships	231	97
Lease liability	261	531
Other accounts receivable reserve	147	65
Amortized intangibles	755	819
Goodwill	358	393
Section 174 Capitalization	583	340
Total deferred tax assets	30,699	27,253
Deferred tax liabilities:
Right of use asset	(205)	(486)
Total deferred tax liabilities	(205)	(486)
Less valuation allowance	(30,494)	(26,767)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Unrecognized tax benefit beginning balance	$ 16	$ 17
Increases for tax positions taken in prior years	0	0
Decreases for tax positions taken in prior years	0	(1)
Increases for tax positions taken in current years	0	0
Settlements	0	0
Unrecognized tax benefit ending balance	$ 16	$ 16

Retirement Benefits - Additiona

Retirement Benefits - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Employer matching contribution, percent	50%
Maximum annual contribution per employee, percent	3%
Description of defined contribution pension and other postretirement plans	Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
Defined benefit plan employee vested minimum period, years	1 year
Amount accrued for company's approved discretionary match	$ 0	$ 0

Segment and Geographic Informat

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2023 Segment
Segment Reporting [Abstract]
Number of operating segment	1

Segment and Geographic Inform_2

Segment and Geographic Information - Summary of Revenues Based on Location of Customers (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 5,330	$ 7,418
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	5,032	6,298
Argentina
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	0	862
India
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	7	7
Canada
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	291	194
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 0	$ 57

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	1,836,987	469,726
Option to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	80,078	60,002
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	266,957	285,757
Preferred Investment Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	1,489,952	123,967

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due	$ 58,000	$ 48,000